Sobetirome Phase I development summary
Peer-reviewed development reviews report Phase I human exposure and LDL-lowering pharmacology, with the programme not progressing to an approved therapy.
What this study tells us
This record relies on a peer-reviewed development review describing historical Phase I human exposure. The primary full trial publication was not located in this evidence pass, so numeric claims should be read as secondary reporting rather than direct primary-trial extraction.
Healthy volunteers / early lipid-development population
n=24
Peer-reviewed development reviews report Phase I human exposure and LDL-lowering pharmacology, with the programme not progressing to an approved therapy.
Primary full trial publication was not located in this pass; numeric regimen/outcome details rely on secondary development summaries.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Peer-reviewed development reviews report Phase I human exposure and LDL-lowering pharmacology, with the programme not progressing to an approved therapy.